Zura Bio Limited ZURA
1.44 USD +0.20 (+16.05%)
Nov 10, 2026, 1:23 PM EST
1.16 Day range 1.53
0.934 52-week range 7.44
- YTD
- -72.54%
- 1 year
- -63.20%
News
benzinga.com Oppenheimer Maintains Outperform on Zura Bio, Lowers Price Target to $5 Oppenheimer analyst Jeff Jones maintains Zura Bio (NASDAQ:ZURA) with a Outperform and lowers the price target from $16 to $5.
benzinga.com Guggenheim Maintains Buy on Zura Bio, Lowers Price Target to $8 Guggenheim analyst Yatin Suneja maintains Zura Bio (NASDAQ:ZURA) with a Buy and lowers the price target from $20 to $8.
businesswire.com ZURA Investors Have Opportunity to Join Zura Bio Limited Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $ZURA--ZURA Investors Have Opportunity to Join Zura Bio Limited Fraud Investigation with SBS Law.
benzinga.com Wedbush Maintains Outperform on Zura Bio, Lowers Price Target to $10 Wedbush analyst Martin Fan maintains Zura Bio (NASDAQ:ZURA) with a Outperform and lowers the price target from $22 to $10.
benzinga.com Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results U.S. stocks surged Monday, led by a 2.1% S&P 500 gain; NRG jumped on strong results, while Zura Bio plunged 75% after trial failures.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
benzinga.com Dow Jumps Over 600 Points; Constellation Energy Posts Upbeat Earnings U.S. stocks rallied Monday, led by tech and consumer discretionary shares. Constellation Energy beat Q3 estimates; oil fell while gold rose.- benzinga.com Zura Bio Says Phase 2 TibuSHIELD Study Of Tibulizumab In Hidradenitis Suppurativa Missed Primary And Key Secondary Endpoints Study did not meet primary endpoint of percentage change from baseline in total abscess and inflammatory nodule (AN) count at Week 16Key secondary endpoints, including HiSCR50 and HiSCR75, were not…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers MaxCyte (NASDAQ:MXCT) stock increased by 21.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $130.0 million. Vir Biotechnology (NASDAQ:VIR)…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com Zura Bio Q3 EPS $(0.20), Inline Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 4.76 percent increase over losses of $(0.21) per share from the same period…
benzinga.com BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led gainers with a 16.3% jump on strong results.
benzinga.com Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22 Wedbush analyst Martin Fan maintains Zura Bio (NASDAQ:ZURA) with a Outperform and raises the price target from $15 to $22.
benzinga.com Guggenheim Maintains Buy on Zura Bio, Raises Price Target to $20 Guggenheim analyst Yatin Suneja maintains Zura Bio (NASDAQ:ZURA) with a Buy and raises the price target from $15 to $20.- benzinga.com Zura Bio Q2 EPS $(0.21) Misses $(0.20) Estimate Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. This is a 23.53 percent decrease over losses of $(0.17) per…
benzinga.com Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy William Blair starts Zura Bio (NASDAQ: ZURA) at Outperform, citing tibulizumab's multibillion-dollar potential in autoimmune disease.- benzinga.com Zura Bio Completes Enrollment In Phase 2 TibuSHIELD Trial of Tibulizumab in Adults With HS Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical developmentTibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants…
benzinga.com Zura Bio Q1 EPS $(0.22) Misses $(0.18) Estimate Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.18) by 22.22 percent. This is a 15.79 percent decrease over losses of $(0.19)…- benzinga.com Zura Bio Announces Separation From CFO Eric Hyllengren; Marlyn Mathew Named Principal Accounting And Principal Financial Officer https://www.sec.gov/ix?doc=/Archives/edgar/data/1855644/000110465926047784/tm2612540d1_8k.htm
benzinga.com AST SpaceMobile, SBC Medical Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures fall around 250 points on Monday. ASTS shares drop 13.5% after satellite placed in lower-than-planned orbit. Other stocks decline in pre-market trading.- benzinga.com Oppenheimer Maintains Outperform on Zura Bio, Lowers Price Target to $15 Oppenheimer analyst Justin Kim maintains Zura Bio (NASDAQ:ZURA) with a Outperform and lowers the price target from $16 to $15.
- benzinga.com Zura Bio Q4 EPS $(0.49) Misses $(0.22) Estimate Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.22) by 122.73 percent. This is a 133.33 percent decrease over losses of…
- benzinga.com Zura Bio Says Design Of Its Ongoing Phase 2 TibuSURE Clinical Trial Evaluating Tibulizumab In SSc Accepted For Presentation At Systemic Sclerosis World Congress Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Zura Bio Limited Reveals Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants; No Size Disclosed Zura Bio Limited (NASDAQ:ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com This Nokia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday 
benzinga.com Wedbush Initiates Coverage On Zura Bio with Outperform Rating, Announces Price Target of $15 Wedbush analyst Martin Fan initiates coverage on Zura Bio (NASDAQ:ZURA) with a Outperform rating and announces Price Target of $15.
benzinga.com Progress Software Posts Upbeat Q4 Earnings, Joins ServisFirst Bancshares, Zura Bio And Other Big Stocks Moving Higher On Wednesday - benzinga.com Zura Bio Appoints Sandeep Kulkarni As CEO, Effective Immediately, Succeeding Kim Davis Zura Bio Limited (Nasdaq: ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with…
benzinga.com Worthington Steel, Immunitybio, Riot Platforms, Micron Technology And Other Big Stocks Moving Higher On Friday - benzinga.com Zura Bio Targets Key 2026–2027 Trial Readouts as Lead Autoimmune Drug Advances, Eyes Transformational Data in 2026 as Tibulizumab Studies Progress Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and…
benzinga.com Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday - benzinga.com Chardan Capital Maintains Buy on Zura Bio, Maintains $10 Price Target Chardan Capital analyst Daniil Gataulin maintains Zura Bio (NASDAQ:ZURA) with a Buy and maintains $10 price target.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44.…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
- benzinga.com Dow Falls Over 100 Points; Analog Devices Posts Upbeat Q2 Earnings U.S. stocks traded lower this morning, with the Dow Jones dropping over 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.44% to 32,908.94 while the NASDAQ fell…
- benzinga.com Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales.
- benzinga.com Why Kura Sushi Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 104% to $5.55 after the company announced it has been selected by the U.S. Department of Defense for a position on the multiple award Indefinite…
benzinga.com PVH, First Republic Bank And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.- benzinga.com Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023.